Senior Scientific Advisors

Steven Schachter, MD
Harvard Medical School, Center for Integration of Medicine and Innovative Technology

Dr. Schachter is Professor of Neurology at Harvard Medical School and Chief Academic Officer and Program Leader of NeuroTechnology for the Center for Integration of Medicine and Innovative Technology (CMIT). He is a Past President of the American Epilepsy Society and a member of the Board of Directors of the Epilepsy Therapy Project. Dr. Schachter is a past Chair of the Professional Advisory Board of the Epilepsy Foundation and served on their Board of Directors. He has directed over 70 research projects involving anti-epileptic therapies and published over 200 articles and book chapters. Dr. Schachter is the founding editor and editor-in-chief of the medical journal Epilepsy & Behavior. He compiled the 6-volume Brainstorms series, which has been distributed to over 150,000 patients and families worldwide in several languages, and has written or edited 23 other books on epilepsy and behavioral neurology. Dr. Schachter received an MD degree from Case Western Reserve University and completed an epilepsy Fellowship at Beth Israel Hospital in Boston

Roger Porter, MD
University of Pennsylvania and Uniformed Services University of the Health Sciences

Dr. Porter is a consultant to academia and to the pharmaceutical industry, primarily in the development of anti-seizure drugs. He is an Adjunct Professor of Neurology at the University of Pennsylvania and Adjunct Professor of Pharmacology at the Uniformed Services University of the Health Sciences (USPHS). Dr. Porter served as Chief Scientific Officer of the Epilepsy Foundation and was most recently the Chief Scientific Officer of the Epilepsy Therapy Project. Previously he held senior management positions and directed worldwide clinical research at Wyeth Pharmaceuticals. Prior to Wyeth, Dr. Porter spent 20 years at the National Institutes of Health (NIH), in leadership positions including Chief of the Epilepsy Branch, Chief of the Medical Neurology Branch and Deputy Director of the National Institute of Neurological Disorders and Stroke. His other leadership positions include Chairman of the White House Committee on Brain and Behavioral Sciences; President, American Epilepsy Society and Secretary-General of the International League against Epilepsy. He is a Past President of the American Society for Experimental NeuroTherapeutics and a Fellow of the American Academy of Neurology. Dr. Porter has published more than 200 articles and chapters and 13 books, and he is the recipient of numerous awards including the Epilepsy Foundation’s 2015 Lifetime Accelerator Award, US Navy Commendation Medal, the Department of Defense Meritorious Service Medal, the USPHS Distinguished Service Medal, the Fulbright Distinguished Professor Award and the Distinguished Alumnus Award from Duke University Medical Center. Dr. Porter received a BS degree from Eckerd College and an MD degree from Duke University.

H. Steve White, PhD
University of Utah College of Pharmacy, Anticonvulsant Drug Development Program

Dr. White is Professor of Pharmacology and Toxicology at the University of Utah College of Pharmacy. He is also the Principal Investigator and Scientific Director of the National Institutes of Health (NIH)-sponsored Anticonvulsant Drug Development Program. This program aims to identify novel anticonvulsant drugs using established animal seizure and epilepsy models and has contributed to the successful development of nine new antiepileptic drugs. Dr. White’s research is focused on understanding the factors that contribute to the initiation, propagation, and amelioration of seizure activity. His laboratory is conducting research that may aid in the identification of disease modifying therapies that halt, slow, or prevent the development of epilepsy in susceptible individuals. He is the author or co-author of more than 70 scientific publications, 100 abstracts and preliminary reports, and 28 book chapters. Dr. White received baccalaureate and masters’ degrees from Idaho State University and a PhD in pharmacology from the University of Utah.